4 completed. 4 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 4 |
| Phase 1 | 2 | Completed 2 |
Follow XL765: new trials by email Literature Review of XL765 trials Research Report on XL765
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer Pimasertib once daily, Pimasertib placebo, SAR245409 placebo - Ovarian Cancer | Phase 2 | Completed | EMD Serono | 65 | 2013-09-30 | 2018-12-12 |
| Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen SAR245408, SAR245409 - Neoplasm Malignant | Phase 1 / Phase 2 | Completed | Sanofi | 61 | 2012-07-20 | 2022-04-19 |
| A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia SAR245409 - Lymphoma | Phase 2 | Completed | Sanofi | 167 | 2011-10-01 | 2016-03-17 |
| Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Breast Cancer XL147 (SAR245408), XL765 (SAR245409), letrozole (Femara) - Breast Cancer | Phase 1 / Phase 2 | Completed | Sanofi | 72 | 2010-06-01 | 2016-06-03 |
Breast Neoplasms (1) · Lymphoma (1) · Neoplasms (1) · Ovarian Neoplasms (1)
Sanofi (3) · EMD Serono (1)
France (4) · United States (4) · Belgium (3) · Spain (3) · Australia (2) · Canada (1) · Germany (1) · Netherlands (1) · Poland (1)